Dupilumab, approved for moderate-to-severe atopic dermatitis, targets:

• A IL-4 alone
• B IL-13 alone
• C IL-31 receptor — reducing pruritus selectively
• D IL-4Rα subunit, thereby blocking both IL-4 and IL-13 signaling ✓

Explanation

Dupilumab is a monoclonal antibody targeting the IL-4 receptor alpha (IL-4Rα) subunit, which is shared by the type I receptor (IL-4 only) and the type II receptor (IL-4 and IL-13). By blocking IL-4Rα, dupilumab simultaneously inhibits both IL-4 and IL-13 signaling — the key Th2 cytokines driving atopic dermatitis pathogenesis. This explains its efficacy across multiple atopic conditions (atopic dermatitis, asthma, CRS with nasal polyps, eosinophilic esophagitis). Nemolizumab targets IL-31RA for prurigo nodularis and atopic dermatitis pruritus.

Reference: Neena Khanna Illustrated Synopsis of Dermatology & STD, 6th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.